Kintara Therapeutics (KTRA) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KTRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KTRA, but not buy additional shares or sell existing shares.
View KTRA analyst ratings or view top-rated stocks.

Kintara Therapeutics' stock was trading at $6.89 at the start of the year. Since then, KTRA stock has decreased by 54.3% and is now trading at $3.15.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023.
View our KTRA earnings forecast.

Kintara Therapeutics, Inc. (NASDAQ:KTRA) posted its earnings results on Thursday, May, 11th. The company reported ($1.94) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $1.84.

Kintara Therapeutics's stock reverse split on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Ampio Pharmaceuticals (AMPE), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA."

Kintara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.63%). Insiders that own company stock include Anthony Scott Praill, Laura L Johnson and Saiid Zarrabian.
View institutional ownership trends.

Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KTRA stock can currently be purchased for approximately $3.15.

Kintara Therapeutics (NASDAQ:KTRA) has a market capitalization of $5.32 million. The company earns $-22,660,000.00 in net income (profit) each year or ($11.04) on an earnings per share basis.

Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.kintara.com. The company can be reached via phone at (858) 350-4364, via email at ir@delmarpharma.com, or via fax at 604-608-5685.